$1.41
-0.09 (-6.00%)
Open$1.48
Previous Close$1.50
Day High$1.48
Day Low$1.30
52W High$29.98
52W Low$1.68
Volume—
Avg Volume86.1K
Market Cap20.78M
P/E Ratio—
EPS$-2.33
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+1,724.8% upside
Current
$1.41
$1.41
Target
$25.73
$25.73
$18.91
$25.73 avg
$33.51
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 872.3K | 3.07M | 47.44M |
| Net Income | 6.29M | 19.96M | 5.52M |
| Profit Margin | 721.9% | 685.8% | 11.6% |
| EBITDA | -10,113,220 | -33,853,273 | 8.75M |
| Free Cash Flow | — | — | 3.59M |
| Rev Growth | -71.6% | -71.6% | +12.6% |
| Debt/Equity | — | — | 0.48 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |